Recent Company News

• 07:00 AM ET May 01, 2025
  

  Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

• 10:14 AM ET Mar 27, 2025
  

  InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell

• 09:25 AM ET Mar 27, 2025
  

  Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

• 07:00 AM ET Mar 17, 2025
  

  Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

• 09:48 AM ET Mar 05, 2025
  

  BioMedNewsBreaks -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters $10 Million Standby Equity Purchase Agreement

• 07:30 AM ET Mar 05, 2025
  

  SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

• 07:10 AM ET Jul 23, 2024
  

  Scinai Immunotherapeutics announces Positive Regulatory Feedback from PEI on path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb ($4.31, 0.00)